Aptevo Therapeutics (APVO) Competitors $3.02 -0.02 (-0.66%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$3.02 +0.00 (+0.03%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. APRE, GTBP, DWTX, KPRX, AEON, LSB, TCRT, SNPX, CHRO, and TSBXShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Aprea Therapeutics (APRE), GT Biopharma (GTBP), Dogwood Therapeutics (DWTX), Kiora Pharmaceuticals (KPRX), AEON Biopharma (AEON), LakeShore Biopharma (LSB), Alaunos Therapeutics (TCRT), Synaptogenix (SNPX), Chromocell Therapeutics (CHRO), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Its Competitors Aprea Therapeutics GT Biopharma Dogwood Therapeutics Kiora Pharmaceuticals AEON Biopharma LakeShore Biopharma Alaunos Therapeutics Synaptogenix Chromocell Therapeutics Turnstone Biologics Aprea Therapeutics (NASDAQ:APRE) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Does the media refer more to APRE or APVO? In the previous week, Aptevo Therapeutics had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Aptevo Therapeutics and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score. Company Overall Sentiment Aprea Therapeutics Neutral Aptevo Therapeutics Neutral Which has more risk and volatility, APRE or APVO? Aprea Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.58, meaning that its stock price is 458% more volatile than the S&P 500. Is APRE or APVO more profitable? Aptevo Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Aprea Therapeutics' return on equity of -68.39% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aprea Therapeutics-1,095.02% -68.39% -55.74% Aptevo Therapeutics N/A -779.42%-175.59% Do analysts prefer APRE or APVO? Aprea Therapeutics currently has a consensus target price of $15.50, suggesting a potential upside of 785.71%. Aptevo Therapeutics has a consensus target price of $219,040.00, suggesting a potential upside of 7,252,880.13%. Given Aptevo Therapeutics' higher probable upside, analysts clearly believe Aptevo Therapeutics is more favorable than Aprea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, APRE or APVO? Aprea Therapeutics has higher revenue and earnings than Aptevo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAprea Therapeutics$1.50M6.45-$12.96M-$2.37-0.74Aptevo TherapeuticsN/AN/A-$24.13MN/AN/A Do institutionals and insiders hold more shares of APRE or APVO? 34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 13.6% of Aprea Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAprea Therapeutics beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.30M$2.91B$5.56B$9.03BDividend YieldN/A2.44%5.22%3.99%P/E RatioN/A21.5627.6920.25Price / SalesN/A241.84389.53161.89Price / CashN/A42.7336.8958.10Price / Book0.057.518.035.67Net Income-$24.13M-$55.14M$3.18B$249.21M7 Day Performance-1.95%4.61%2.93%3.28%1 Month Performance-38.99%0.90%1.72%3.95%1 Year Performance-99.96%5.40%34.39%20.98% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics2.1174 of 5 stars$3.02-0.7%$219,040.00+7,252,880.1%-100.0%$2.30MN/A0.0050APREAprea Therapeutics2.5158 of 5 stars$1.69+0.9%$15.50+817.2%-54.9%$9.27M$1.50M-0.717GTBPGT Biopharma1.4174 of 5 stars$3.58+1.1%$11.00+207.3%-1.9%$9.16MN/A-0.638DWTXDogwood Therapeutics1.1586 of 5 stars$4.77+1.3%$10.00+109.6%N/A$9MN/A-0.265News CoveragePositive NewsKPRXKiora Pharmaceuticals2.2984 of 5 stars$2.88-0.7%$10.00+247.2%-37.6%$8.83M$16.02M-0.9910Positive NewsAEONAEON Biopharma3.5162 of 5 stars$0.76+0.1%$360.00+47,268.4%-98.8%$8.59MN/A4.225LSBLakeShore Biopharma0.3358 of 5 stars$1.02+11.0%N/AN/A$8.55M$80.82M0.00773Positive NewsGap UpHigh Trading VolumeTCRTAlaunos Therapeutics0.4864 of 5 stars$4.85-5.5%N/A-22.7%$8.41M$10K-1.9140SNPXSynaptogenix1.1515 of 5 stars$7.85+29.8%$14.00+78.3%+106.8%$8.40MN/A-0.784Gap DownHigh Trading VolumeCHROChromocell TherapeuticsN/A$1.26-6.7%N/A-89.1%$8.31MN/A-1.024Gap UpTSBXTurnstone Biologics1.2162 of 5 stars$0.36+1.8%$0.45+25.3%-83.8%$8.16M$19.31M-0.1382High Trading Volume Related Companies and Tools Related Companies APRE Alternatives GTBP Alternatives DWTX Alternatives KPRX Alternatives AEON Alternatives LSB Alternatives TCRT Alternatives SNPX Alternatives CHRO Alternatives TSBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
